Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10833064 | 0.89 | LMNA (0.56) | AKR1C3MAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL10558279 | 0.89 | AKR1C3 (0.50) | AKR1C3MAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL4565279 | 0.89 | AKR1C3 (0.50) | AKR1C3MAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL1619240 | 0.85 | MAPT (0.52) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5866992 | 0.85 | MAPT (0.49) | MAPTALDH1A1TSHRHSD17B10NPC1 | |
| SCHEMBL29459930 | 0.84 | MRGPRX4 (0.61) | AKR1C3NPC1RAB9ANR4A2KMT2A | |
| SCHEMBL496275 | 0.84 | MRGPRX4 (0.61) | AKR1C3NPC1RAB9ANR4A2KMT2A | |
| SCHEMBL4035515 | 0.83 | MAPT (0.56) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30744738 | 0.82 | MRGPRX4 (0.63) | AKR1C3MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1965898 | 0.82 | MRGPRX4 (0.63) | AKR1C3MAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| EP-3002280-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2023-05-24 | — | — | EP | disclosed |
| CN-106478497-B | Arylamine derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| US-9862691-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2018-01-09 | — | — | US | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2016-10-27 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | NOVARTIS AG (CH) | 2006-12-28 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1635835-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110452-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-4832879-A | INTERMEDIATES FOR HERBICIDES | BASF AKTIENGESELLCHAFT (DE) | 1989-05-23 | — | — | US | disclosed |
| US-RE32087-E | 4H-3,1-Benzoxazine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1986-02-25 | — | — | US | disclosed |
| EP-0084893-A2 | 4H-3,1-Benzoxazin derivatives, methods for their preparation, and their use for combatting undesirable vegetation | BASF Aktiengesellschaft (DE) | 1983-08-03 | — | — | EP | disclosed |
| US-4315766-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | AKR1C3 535/4885MAPT 1770/4885ALDH1A1 1448/4885 |
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | AKR1C3 447/4885MAPT 4216/4885ALDH1A1 459/4885 |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | SCN1A, SCN1B, SCN3A | AKR1C3 620/4885MAPT 3135/4885ALDH1A1 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.